Adaptive T cell immunotherapy in cancer

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Impaired tumor-specific effector T cells lead to cancer progression.
• Adoptive T cell therapy (ACT) is a T cell-dependent cancer immunoediting strategy with encouraging results.
• ACT is a central focus in cancer treatment and research.

Purpose of the Study:

• To provide an overview of current developments in ACT strategies.
• To focus on frontier clinical trials demonstrating the principle of ACT.
• To discuss insights into ACT determinants for improved future applications.

Main Methods:

• Ex vivo stimulation and expansion of tumor-infiltrating lymphocytes (TILs) or genetically modified T cells (CAR/TCR).
• Passive transfer of primed T cells into a lymphodepleted host.
• Review of current ACT strategies and clinical trials.

Main Results:

• ACT has achieved encouraging therapeutic results in cancer treatment.
• Frontier clinical trials offer a proof of principle for ACT efficacy.
• Understanding ACT mechanisms is crucial for improving current strategies.

Conclusions:

• Further understanding of ACT mechanisms can lead to improved next-generation immunotherapies.
• Insights into ACT determinants will enable more rational, potent, and widespread applications.
• Optimizing T cell-based immunotherapies holds significant potential for cancer treatment.